TSLA
Tesla
-- 431.660 RGTI
Rigetti Computing
-- 17.0800 NVDA
NVIDIA
-- 137.010 PLTR
Palantir
-- 79.080 LAES
SEALSQ Corp
-- 9.080 
NEWS
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) for Q1 2025. The company reported research and development costs of $2.9M, marking a $0.3M increase from Q1 2024. IXHL recovered 28.0% of these costs through an R&D tax incentive of $0.8M, with expectations of normalization around 43.5%.
The company has completed dosing for its Phase 2/3 FDA trial for Obstructive Sleep Apnea treatment and received FDA IND clearance for PSX-001, targeting Generalized Anxiety Disorder. Stonegate's probability-adjusted DCF model suggests a per share valuation range of $5.07 to $5.93.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment